We advised JOINN Laboratories on its IPO and HKEX listing.

Â鶹Èë¿Ú advised JOINN Laboratories (China) Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and a global offering in reliance on Rule 144A and Regulation S. The gross proceeds from the offering amounted to HK$6.5 billion (US$844 million) prior to any exercise of the over-allotment option. This is the largest biopharmaceutical IPO in Greater China and the largest Hong Kong offering by an A-share listed company since Â鶹Èë¿Ú advised Tigermed on its IPO in 2020.

JOINN Laboratories is a non-clinical CRO focused on drug safety assessment, with an expanding portfolio of R&D services covering discovery, pre-clinical and clinical trial stages in the drug R&D service chain. The A shares of JOINN Laboratories have been listed on the Shanghai Stock Exchange (stock code: 603127) since August 2017.

The Â鶹Èë¿Ú corporate team included partners Li He and Yang Chu, counsel – registered foreign lawyer Kevin Zhang, counsel Kai Sun and associate Edwin Lee. Associate Veronica Davis provided tax advice. Members of the Â鶹Èë¿Ú team are based in the Hong Kong and London offices.

Copy link to share post